ClinicalTrials.govpublic full text
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
msi-h/dmmr solid tumors, msi-h/dmmr, solid tumors, pd-1, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 802675
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.